NYSE: GMED

Globus Medical (GMED) Stock Analysis & Forecast

Nov 13 close

$72.14−0.16 (−0.2%)

Gekko Brief

AI summaryNov 9 close

Globus Medical moves this week on third-quarter results and a lowered 2026 revenue outlook. The company reported Q3 2026 earnings that topped estimates, compared with $1.18 per share a year ago, while management cited continued declines at its Nevro business, delayed spine product launches, and lower contributions from competitive sales recruiting as reasons for the guidance cut and a shift in focus toward new products and growth opportunities in 2027. Alongside the results, Globus Medical announced a $500 million increase to its share repurchase program, and separate commentary described the company as the second-largest player in the spine industry with a narrow moat following its NuVasive merger and Nevro acquisition. The company is also set to participate in the Jefferies Global Healthcare Conference in London.

Shares closed at $76.37, up 7.5%, but remain below both the 50-day average of $77.07 and the 200-day average of $83.06, with the 50-day below the 200-day. The GekkoIndex reads 58.8, placing the stock in the Neutral zone, up 3.4 over five sessions. Price sits 0.4% below Gekko Fair Value of $76.66.

The next earnings date is 23 February 2027, outside a typical 20-day holding window. Over the last 90 days, Congress recorded 2 buys and 0 sells, while the last 30 days show 2 unusual options signals with put premium of $944,594 and no call premium. Seasonally, the next 20 trading days have averaged -0.2% over 5 years, rising in 3 of them, a mixed backdrop worth noting.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Globus Medical price vs fair value

$72.14$72.10Nov ’25May ’26Nov ’26
Close $72.14200-day averageGekko Fair Value $72.10

Globus Medical quick facts

Market cap
$9.57B
P/E ratio
17.8
Forward P/E
14.1
EPS, TTM
$4.06
Revenue, TTM
$3.14B
Profit margin
17.8%
Dividend yield
—
Beta
0.95
Volume
1.54M avg 2.01M
1-year return
−14.8%
Typical daily move
±5.6%
Typical 20-day move
±6%
50-day average
$76.55
200-day average
$82.70
Next earnings
Feb 23 after close
Shares outstanding
110.2M
52-week range
$70.40$101.40

Globus Medical swing-trade checklist

Globus Medical scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $72.14 is below the 50-day ($76.55) and 200-day ($82.70) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    62.1, Accumulation

    Reading 62.1 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuemixed

    0.1% above

    Price is within 5% of Gekko Fair Value (0.1% above).

    See fair value
  • Smart moneymixed

    Mixed

    Last 90 days: Congress 2 buys / 0 sales. Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.1% on average

    From this point in the calendar, the next 20 trading days averaged +2.1% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Globus Medical stock chart and price history

Globus Medical closed at $72.14 on Nov 13, 2026, −14.8% over the past year, inside a 52-week range of $70.40 to $101.40.

Close50-day average200-day averageVolume
Globus Medical share price, past year, with 50-day and 200-day moving averages and volume$60$80$90DecJan 2026FebMarAprMayJunJulAugSepOctNov72.14

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−8.5%
3 months
−15.2%
6 months
−5.9%
1 year
−14.8%
The full GMED chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GMED in Gekko

Follow Globus Medical through every session

Put GMED on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GMED in GekkoFree for 7 days. No credit card required.

About Globus Medical

Globus Medical designs, builds, and sells medical devices used to treat disorders of the bones, joints, and spine. It is best known for its spinal care offerings, which range from fusion hardware such as pedicle screw and rod systems, plating systems, and spacers, to motion-preserving options like disc replacements and dynamic stabilization devices, along with tools for managing vertebral compression fractures.

Its product lines extend beyond the spine into orthopedic trauma care, with plates, screws, nails, and fixation systems for fractures, as well as joint reconstruction devices for the hip and knee, including stems, cups, and arthroplasty implants. The company also supplies regenerative biologic materials, such as allografts and synthetic substitutes, and distributes cell- and tissue-based products, serving patients and clinicians who treat musculoskeletal conditions such as degenerative disease, deformity, tumors, and trauma.

Globus Medical was founded in 2003 and is headquartered in Audubon, Pennsylvania. Its shares are listed on the NYSE under the ticker GMED.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
globusmedical.com

Globus Medical GekkoIndex: the smart money zone

Globus Medical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.1, in the Accumulation zone, up 0.8 points over five sessions.

010062.1Accumulation

Up 0.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying48+1.5%+1.7%+2.3%−2.4%
Accumulation (current zone)247+0.3%+0.9%+2.1%+4.6%
Neutral345+0.3%+0.6%+1.9%+5.7%
Distribution55+0.9%+0.8%−1.1%−0.4%
Selling7Too few readings yet

Average GMED share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the GMED price, zone by zone.Track GMED in Gekko

Is Globus Medical stock overvalued? Gekko Fair Value

Globus Medical trades 0.1% above Gekko Fair Value of $72.10, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Globus Medical shares are worth, recalculated every trading day.

$72.10

Gekko Fair Value, Nov 14, 2026

0.1% above fair value · About fair value

At the end of Aug 2026 the price was 12.2% above the estimate.

Gekko Fair ValueShare price, month end
$72$72Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GMED in Gekko

Globus Medical insider and Congress trading

No open-market insider purchases were filed for Globus Medical, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GMED in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GMED insider filing, plotted on the chart in Gekko.Open GMED in Gekko

Congress trades last 90 days

2trades disclosed: 2 purchases and 0 sales.

MemberTypeAmountDisclosed
Gilbert Cisneros
House, CA, purchase
Purchase$1,001 - $15,000Oct 12
traded Sep 3
Gilbert Cisneros
House, CA, purchase
Purchase$15,001 - $50,000Sep 11
traded Aug 19

From congressional disclosures, which report amounts as ranges.

Buybacks

Globus Medical has been buying back its own shares.

Latest authorization
$500.0M, Nov 5, 2026
Bought back, quarter ended Sep 30, 2026
$142.9M
As a share of market cap
1.49%

From company filings.

Unusual options activity last 30 days

2signals, 0% of the flagged premium in calls.

Latest: Bearish flow on Nov 6, $481K in unusual premium.

Every signal with its contract, strike and premium.Unlock in Gekko

Globus Medical earnings: next date and track record

Globus Medical reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±12.8%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+10.7%Nov ’24−4.5%Feb ’25−21.9%May ’25+11.0%Aug ’25+36.4%Nov ’25+3.0%Feb ’26−12.6%May ’26+2.2%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Globus Medical reported Q2 2026 revenue of $789.6 million, up 6% as reported (9% excluding Nevro). Non-GAAP EPS grew 56% YoY to $1.34, with adjusted EBITDA margin of 35.4%, up 740 bps. U.S. Spine grew 7%, International Spine 14%, and Trauma surged 31%. The company repurchased $136 million in shares and has launched 25+ products over 36 months while continuing aggressive competitive recruiting.
Guidance
Management expressed confidence in a strong second half of 2026, citing sustained market share gains, expanding trauma portfolio, Nevro integration, and broad-based organic growth. No specific revenue or EPS targets were provided in this excerpt.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$1.34
est $1.10
+21.8%$789.6M
est $782.9M
+0.9%+2.2%
May 7, 2026$1.12
est $0.92
+21.7%$759.9M
est $740.3M
+2.6%−12.6%
Feb 24, 2026$1.28
est $1.15
+11.0%$826.4M
est $801.7M
+3.1%+3.0%
Nov 6, 2025$1.18
est $0.77
+53.2%$769.0M
est $734.7M
+4.7%+36.4%
Aug 7, 2025$0.86
est $0.75
+14.7%$745.3M
est $742.7M
+0.4%+11.0%
May 8, 2025$0.68
est $0.74
−8.1%$598.1M
est $625.9M
−4.4%−21.9%
Feb 20, 2025$0.84
est $0.75
+12.2%$657.3M
est $645.7M
+1.8%−4.5%
Nov 5, 2024$0.83
est $0.65
+27.7%$625.7M
est $604.7M
+3.5%+10.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Globus Medical stock forecast and analyst price targets

Analysts’ average 12-month price target for Globus Medical is $93.43, +29.5% from the last close, from 9 firms rating the stock in the last 90 days.

$93.43consensus 12-month target, +29.5% from the last close
Low $76.43High $105
Buy6
Hold3
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 6Wells FargoBuy, reiterated$100+38.6%
Nov 6Piper SandlerBuy, reiterated$100+38.6%
Nov 6Canaccord GenuityBuy, maintained$105+45.6%
Nov 6BMO CapitalHold, downgraded$78+8.1%
Nov 6Bank of America SecuritiesBuy, maintained——
+2.1%average 20-day move after past Accumulation readings
+2.1%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Globus Medical seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Globus Medical averaged +2.1% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−4.0%2021+4.5%2022+7.3%2023+1.6%2024+2.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.8%2 of 5
Next 10 trading days−0.7%3 of 5
Next 15 trading days−0.6%2 of 5
Next 20 trading days+2.1%4 of 5
Next 30 trading days+5.8%5 of 5

For scale, GMED’s typical 20-trading-day move in either direction is about 6%.

Globus Medical market cap and key statistics

Globus Medical’s market cap is $9.57B, with a P/E ratio of 17.8 and revenue of $3.14B over the last twelve months.

Valuation

Market cap
$9.57B
P/E ratio
17.8
Forward P/E
14.1
EPS, TTM
$4.06
Gekko Fair Value
$72.10

Trading

Volume
1.54M
Avg volume, 20 days
2.01M
52-week high
$101.40
52-week low
$70.40
Shares outstanding
110.2M

Financials

Revenue, TTM
$3.14B
Profit margin
17.8%
Return on equity
12.1%
Quarterly earnings growth, YoY
+18.2%

Risk and income

Beta
0.95
Typical daily move
±5.6%
Typical 20-day move
±6%

Globus Medical stock news this week

Coverage of Globus Medical this week reads negative: 1 positive, 1 neutral and 5 negative headlines.

News sentiment negative

Globus Medical peers

Globus Medical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Globus Medical stock FAQ

What is Globus Medical’s market cap?

Globus Medical’s market cap is $9.57B at the Nov 13, 2026 close of $72.14, with 110.2M shares outstanding. The shares trade on a P/E ratio of 17.8.

What is the Globus Medical stock forecast?

The consensus analyst 12-month price target for Globus Medical is $93.43, +29.5% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Globus Medical stock overvalued or undervalued?

On Gekko’s estimate Globus Medical is about fair value: the Nov 13, 2026 close of $72.14 is 0.1% above Gekko Fair Value of $72.10. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Globus Medical report earnings next?

Globus Medical is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $1.30 per share on revenue of $783.4M. Globus Medical beat the earnings estimate in 7 of its last 8 reports, moving 12.8% on average across the report.

What is Globus Medical’s 52-week high and low?

Globus Medical’s 52-week high is $101.40 and its 52-week low is $70.40; it closed at $72.14 on Nov 13, 2026, −14.8% over the past year.

Is Globus Medical stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, earnings risk and seasonality), 2 as mixed (fair value and smart money) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Globus Medical?

Gekko flagged 2 unusual options signals in Globus Medical over the last 30 days, with $0 of flagged premium in calls and $945K in puts. The latest, bearish flow, was on Nov 6, 2026 with $481K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Globus Medical the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.